Atlas Trials

The Metabolic Effects of Empagliflozin in Patients With High Risk of Heart Failure

Clinical trial NCT05042973 · COMPLETED

Trial details

NCT number
NCT05042973
Sponsor
Jacob Moller
Status
COMPLETED
Phase
Phase 2
Study type
INTERVENTIONAL
ObesityHeart Failure
Start date
2021-09-02
Primary completion
2025-01-16
Enrollment
165

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.